Items tagged with Drug-resistant TB
Have your say! Survey on drug-resistant TB treatment options (post)
In December 2017, Treatment Action Group (TAG), ACTION and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) conducted a webinar on the results of two phase III trials for treating rifampicin-resistant TB.
Survival outcomes improved with concurrent treatment for multidrug-resistant TB and HIV (post)
Treatment of multidrug-resistant tuberculosis (TB) has comparable efficacy and survival rates in patients infected with HIV and not uninfected with HIV when patients with HIV are given antiretroviral therapy, according to the results of recent research published in Clinical Infectious Diseases.
ZeNix clinical trial announced (post)
NEW YORK (7 February, 2018) — TB Alliance has announced the start of a clinical trial of a three-drug regimen to treat extensively drug resistant tuberculosis (XDR-TB)—one of the deadliest forms of tuberculosis (TB)—and those with pre-XDR-TB and multi-drug resident TB (MDR-TB) whose prior treatment has failed or who have not tolerated their treatment.
Three more hospitals in India get approval to administer bedaquiline (post)
Apart from KEM, Nair Hospital, Sion Hospital and Govandi’s Shatabdi Hospital will be able to administer bedaquiline to drug-resistant tuberculosis patients.
Comprehensive care and support significantly boosts MDR-TB successful treatment completion (post)
A Taiwan program of comprehensive support and care centered on the needs of patients being treated for multidrug-resistant tuberculosis — at a cost of from $25,000 to $30,000 per patient, per year over the costs of medicines — substantially improved cure rates and drastically reduced rates of patients whose outcomes were unknown, according to a study reported in Clinical Infectious Diseases.
Promising MSF research highlights immense benefits, need for expanded use of DR-TB drug combination (post)
NEW YORK, FEBRUARY 14, 2018—New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease. These findings encourage the wider use of these medicines in combination for DR-TB patients worldwide.
How both sides in Ukraine’s war are losing the HIV battle (post)
Displacement, aid delivery issues, and different strategies are all feeding a raging epidemic
Report of the WHO webinar for civil society and partners on TB guidelines development (post)
The World Health Organization (WHO) Global TB Programme convened a webinar on the WHO guideline development process, with a focus on guidelines for the management of multidrug-resistant TB (MDR-TB). The webinar was held on 27 February 2018, based on a request from civil society participants at a WHO meeting in January 2018 to discuss the process, format, and dissemination of WHO guidelines. The webinar was attended by more than 60 participants. Tereza Kasaeva, Director of the WHO Global TB Programme, opened the event and welcomed participants. The webinar was moderated by Haileyesus Getahun, Coordinator of TB/HIV and Community Engagement, Global TB Programme.
Lifestyle choices could boost drug-resistant TB, shows new study (post)
A new study conducted by Pallavi Sinha and group from Institute of Medical Sciences, Banaras Hindu University and Boston Medical Centre has concluded that behavioral factors, like alcohol consumption and smoking, and clinical factors, like previous TB treatment, increases the risk of multidrug-resistant TB (MDR-TB).
WHO launches plan for cheaper TB drugs (post)
The World Health Organisation (WHO), on Tuesday (March 6), invited pharmaceutical companies around the world to submit proposals to manufacture affordable versions of newer medicines for treatment of drug-resistant tuberculosis (DR-TB).
Page 48 of 117 · Total posts: 0
←First 47 48 49 Last→